Allogene Therapeutics (ALLO) Competitors $1.23 +0.06 (+5.13%) Closing price 09/24/2025 04:00 PM EasternExtended Trading$1.21 -0.02 (-1.63%) As of 06:27 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALLO vs. ATAI, SPRY, CRON, CRMD, UPB, SYRE, QURE, URGN, RAPP, and ABUSShould you be buying Allogene Therapeutics stock or one of its competitors? The main competitors of Allogene Therapeutics include atai Life Sciences (ATAI), ARS Pharmaceuticals (SPRY), Cronos Group (CRON), CorMedix (CRMD), Upstream Bio (UPB), Spyre Therapeutics (SYRE), uniQure (QURE), Urogen Pharma (URGN), Rapport Therapeutics (RAPP), and Arbutus Biopharma (ABUS). These companies are all part of the "pharmaceutical products" industry. Allogene Therapeutics vs. Its Competitors atai Life Sciences ARS Pharmaceuticals Cronos Group CorMedix Upstream Bio Spyre Therapeutics uniQure Urogen Pharma Rapport Therapeutics Arbutus Biopharma atai Life Sciences (NASDAQ:ATAI) and Allogene Therapeutics (NASDAQ:ALLO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation and profitability. Do analysts rate ATAI or ALLO? atai Life Sciences presently has a consensus target price of $11.25, indicating a potential upside of 104.92%. Allogene Therapeutics has a consensus target price of $8.44, indicating a potential upside of 586.54%. Given Allogene Therapeutics' higher possible upside, analysts clearly believe Allogene Therapeutics is more favorable than atai Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score atai Life Sciences 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.17Allogene Therapeutics 0 Sell rating(s) 3 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.75 Which has better earnings and valuation, ATAI or ALLO? atai Life Sciences has higher revenue and earnings than Allogene Therapeutics. atai Life Sciences is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratioatai Life Sciences$310K3,795.89-$149.27M-$0.69-7.96Allogene TherapeuticsN/AN/A-$257.59M-$1.11-1.11 Does the media favor ATAI or ALLO? In the previous week, atai Life Sciences had 12 more articles in the media than Allogene Therapeutics. MarketBeat recorded 14 mentions for atai Life Sciences and 2 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 1.67 beat atai Life Sciences' score of 0.50 indicating that Allogene Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment atai Life Sciences 6 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Allogene Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do institutionals and insiders believe in ATAI or ALLO? 28.4% of atai Life Sciences shares are held by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are held by institutional investors. 26.8% of atai Life Sciences shares are held by company insiders. Comparatively, 13.2% of Allogene Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more risk and volatility, ATAI or ALLO? atai Life Sciences has a beta of 1.55, suggesting that its stock price is 55% more volatile than the S&P 500. Comparatively, Allogene Therapeutics has a beta of 0.36, suggesting that its stock price is 64% less volatile than the S&P 500. Is ATAI or ALLO more profitable? Allogene Therapeutics' return on equity of -55.99% beat atai Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets atai Life SciencesN/A -85.43% -64.38% Allogene Therapeutics N/A -55.99%-42.75% Summaryatai Life Sciences beats Allogene Therapeutics on 8 of the 15 factors compared between the two stocks. Get Allogene Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALLO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALLO vs. The Competition Export to ExcelMetricAllogene TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$259.60M$3.14B$5.78B$10.41BDividend YieldN/A2.36%5.68%4.62%P/E Ratio-1.1120.7675.9926.42Price / SalesN/A402.55543.86179.21Price / CashN/A45.9137.5661.52Price / Book0.619.8312.956.39Net Income-$257.59M-$52.73M$3.29B$271.13M7 Day Performance1.65%1.84%0.81%0.93%1 Month Performance6.03%7.48%4.95%7.52%1 Year Performance-53.05%19.92%68.72%30.06% Allogene Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALLOAllogene Therapeutics3.2799 of 5 stars$1.23+5.1%$8.44+586.5%-53.9%$259.60MN/A-1.11310Positive NewsATAIatai Life Sciences3.2607 of 5 stars$4.65+0.4%$11.25+141.9%+365.3%$992.39M$310K-6.7480Analyst ForecastGap UpSPRYARS Pharmaceuticals2.8215 of 5 stars$9.96-0.7%$32.50+226.3%-29.6%$991.23M$89.15M-20.3390CRONCronos Group2.2159 of 5 stars$2.55+0.8%N/A+26.0%$968.72M$117.61M51.00450CRMDCorMedix3.8842 of 5 stars$12.65-2.2%$18.00+42.3%+49.7%$965.96M$43.47M16.8730Positive NewsUPBUpstream Bio1.452 of 5 stars$16.79-4.4%$56.50+236.5%N/A$947.19M$2.37M0.0038SYRESpyre Therapeutics2.4206 of 5 stars$14.84-5.2%$53.40+259.8%-39.6%$945.28M$890K-4.3673High Trading VolumeQUREuniQure2.0115 of 5 stars$14.84-10.0%$37.45+152.4%+824.1%$904.48M$27.12M-3.79500Trending NewsAnalyst ForecastGap UpHigh Trading VolumeURGNUrogen Pharma4.1444 of 5 stars$18.06-3.9%$32.00+77.2%+37.7%$869.30M$90.40M-5.44200Positive NewsRAPPRapport Therapeutics3.0731 of 5 stars$24.73+4.1%$31.00+25.4%+26.0%$867.19MN/A-9.89N/AABUSArbutus Biopharma1.3033 of 5 stars$4.53+1.6%$5.00+10.4%+11.7%$854.98M$6.17M-15.6290 Related Companies and Tools Related Companies ATAI Competitors SPRY Competitors CRON Competitors CRMD Competitors UPB Competitors SYRE Competitors QURE Competitors URGN Competitors RAPP Competitors ABUS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALLO) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allogene Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allogene Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALLO Stock Alerts